Literature DB >> 25034061

Predictors of an inadequate defibrillation safety margin at ICD implantation: insights from the National Cardiovascular Data Registry.

Jonathan C Hsu1, Gregory M Marcus2, Sana M Al-Khatib3, Yongfei Wang4, Jeptha P Curtis4, Nitesh Sood5, Matthew W Parker6, Jeffrey Kluger6, Rachel Lampert4, Andrea M Russo7.   

Abstract

BACKGROUND: Defibrillation testing is often performed to establish effective arrhythmia termination, but predictors and consequences of an inadequate defibrillation safety margin (DSM) remain largely unknown.
OBJECTIVES: The aims of this study were to develop a simple risk score predictive of an inadequate DSM at implantable cardioverter-defibrillator (ICD) implantation and to examine the association of an inadequate DSM with adverse events.
METHODS: A total of 132,477 ICD Registry implantations between 2010 and 2012 were analyzed. Using logistic regression models, factors most predictive of an inadequate DSM (defined as the lowest successful energy tested <10 J from maximal device output) were identified, and the association of an inadequate DSM with adverse events was evaluated.
RESULTS: Inadequate DSMs occurred in 12,397 patients (9.4%). A simple risk score composed of 8 easily identifiable variables characterized patients at high and low risk for an inadequate DSM, including (with assigned points) age <70 years (1 point); male sex (1 point); race: black (4 points), Hispanic (2 points), or other (1 point); New York Heart Association functional class III (1 point) or IV (3 points); no ischemic heart disease (2 points); renal dialysis (3 points); secondary prevention indication (1 point); and ICD type: single-chamber (2 points) or biventricular (1 point) device. An inadequate DSM was associated with greater odds of complications (odds ratio: 1.22; 95% confidence interval: 1.09 to 1.37; p = 0.0006), hospital stay >3 days (odds ratio: 1.24; 95% confidence interval: 1.19 to 1.30; p < 0.0001), and in-hospital mortality (odds ratio: 1.96; 95% confidence interval: 1.63 to 2.36; p < 0.0001).
CONCLUSIONS: A simple risk score identified ICD recipients at risk for an inadequate DSM. An inadequate DSM was associated with an increased risk for in-hospital adverse events.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adverse events; complications; defibrillation safety margin; defibrillation threshold; implantable cardioverter-defibrillator; mortality; national registries; risk score

Mesh:

Year:  2014        PMID: 25034061     DOI: 10.1016/j.jacc.2014.01.085

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  A Novel Defibrillation Tool: Percutaneously Delivered, Partially Insulated Epicardial Defibrillation.

Authors:  Ammar M Killu; Niyada Naksuk; Zdeněk Stárek; Christopher V DeSimone; Faisal F Syed; Prakriti Gaba; Jiří Wolf; Frantisek Lehar; Martin Pesl; Pavel Leinveber; Michal Crha; Dorothy Ladewig; Joanne Powers; Scott Suddendorf; David O Hodge; Gaurav Satam; Miroslav Novák; Tomas Kara; Charles J Bruce; Paul A Friedman; Samuel J Asirvatham
Journal:  JACC Clin Electrophysiol       Date:  2017-07

2.  Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States.

Authors:  Daniel J Friedman; Craig S Parzynski; Paul D Varosy; Jordan M Prutkin; Kristen K Patton; Ali Mithani; Andrea M Russo; Jeptha P Curtis; Sana M Al-Khatib
Journal:  JAMA Cardiol       Date:  2016-11-01       Impact factor: 14.676

Review 3.  The Saga of Defibrillation Testing: When Less Is More.

Authors:  Marye J Gleva; Melissa Robinson; Jeanne Poole
Journal:  Curr Cardiol Rep       Date:  2018-05-05       Impact factor: 2.931

4.  Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry.

Authors:  Daniel J Friedman; Craig S Parzynski; E Kevin Heist; Andrea M Russo; Joseph G Akar; James V Freeman; Jeptha P Curtis; Sana M Al-Khatib
Journal:  Circulation       Date:  2018-02-20       Impact factor: 29.690

Review 5.  Subcutaneous and Transvenous ICDs: an Update on Contemporary Questions and Controversies.

Authors:  Daniel J Friedman; Albert S Tully; Emily P Zeitler
Journal:  Curr Cardiol Rep       Date:  2022-05-31       Impact factor: 3.955

6.  Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial.

Authors:  Dietmar Bänsch; Hendrik Bonnemeier; Johan Brandt; Frank Bode; Jesper Hastrup Svendsen; Miloš Táborský; Stefan Kuster; Carina Blomström-Lundqvist; Angelika Felk; Tino Hauser; Anna Suling; Karl Wegscheider
Journal:  Eur Heart J       Date:  2015-06-25       Impact factor: 29.983

7.  Subcutaneous implantable cardioverter-defibrillator placement in a patient with a preexisting transvenous implantable cardioverter-defibrillator.

Authors:  Mohammad-Ali Jazayeri; Martin P Emert; JoAnn Bartos; Ted Tabbert; Dhanunjaya R Lakkireddy; Mohammad-Reza Jazayeri
Journal:  HeartRhythm Case Rep       Date:  2017-05-25

Review 8.  Implantable Cardioverter-Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review.

Authors:  Ryan T Borne; David Katz; Jarrod Betz; Pamela N Peterson; Frederick A Masoudi
Journal:  J Am Heart Assoc       Date:  2017-03-03       Impact factor: 5.501

9.  Left axillary active can positioning markedly reduces defibrillation threshold of a transvenous defibrillator failing to defibrillate at maximum output.

Authors:  Raman L Mitra
Journal:  HeartRhythm Case Rep       Date:  2018-10-23

10.  Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice.

Authors:  Ryan T Borne; Tiffany Randolph; Yongfei Wang; Jeptha P Curtis; Pamela N Peterson; Frederick A Masoudi; Amneet Sandhu; Matthew M Zipse; Kevin Thomas; Valentina Kutyifa; Nihar R Desai; Yong-Mei Cha; Jonathan C Hsu; Andrea M Russo
Journal:  JAMA Netw Open       Date:  2019-10-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.